Chris Bryant

I could read out the long list of investments made in the last few months, except I do not think that Mr Speaker would let me. I do not think we have time, and you would get bored with me, Mr Speaker. The hon. Member makes an important point. At the moment, I am engaged in negotiations on a significant possible investment. We must ensure that we are delivering value for money for the British taxpayer, and that we are not throwing money away unnecessarily. Of course, there comes a moment when we have to make a judgment, and we made a judgment that came remarkably close to the £90 million offered by the previous Chancellor of the Exchequer, despite the fact that AstraZeneca’s R&D contribution had gone down from £150 million to £90 million. We made a significant offer, but for whatever reason, it did not get it over the line. Obviously, we always want to get deals over the line if we possibly can, and there are competing demands for different kinds of investment, but I assure the hon. Member that our aim is always to try to make sure that we are at the forefront of all the nations seeking such investment, especially in this kind of technology. The hon. Member is right about Northern Ireland. I, as a Welshman, bang the drum for Wales, and he bangs the drum for Northern Ireland—and quite rightly so.